Due to its success in the preclinical setting with different ALK fusion partners, EML4 variants, and tumor contexts, NVL-655 is undergoing further evaluation in the phase I/II ALKOVE-1 trial (NCT05384626)[120]. This evidence concerns the gene ALK and neoplasm.